Obesity:肥胖是一种慢性病!美国学者提议建立肥胖ICD编码

2020-02-25 xujing 中国循环杂志

研究者提出的国际疾病分类(ICD)编码系统基于美国临床内分泌学家协会(AACE)提出的肥胖型慢性病(Adiposity-Based Chronic Disease,ABCD)的诊断,这个诊断术语反映了肥胖作为一种慢性疾病的病理生理学和临床影响。

美国学者在《肥胖》杂志发表文章,建议亟待建立一个更科学准确、医学上可行的新的肥胖疾病分类系统。
 
研究者提出的国际疾病分类(ICD)编码系统基于美国临床内分泌学家协会(AACE)提出的肥胖型慢性病(Adiposity-Based Chronic Disease,ABCD)的诊断,这个诊断术语反映了肥胖作为一种慢性疾病的病理生理学和临床影响。
 
该ICD编码系统包括四个领域:A码反映病理生理学,B码表示BMI分级,C码表示可通过减肥治疗的特定生物力学和心血管并发症,D码表示并发症的严重程度。补充代码确定了使护理复杂化和与个性化治疗计划相关的加重因素。
 
目前,肥胖的诊断仅基于BMI,而BMI没有显示肥胖对人类健康的影响。ICD代码中写着“因热量摄入过多而肥胖”。
 
研究者指出,这在医学上没有意义,也不能反映肥胖的发病机制,并且没有把肥胖视为一种慢性病。肥胖不能简单认为是患者吃得太多,不够活跃。
 
研究者认为,现在是肥胖进入精确医学时代的时候了,新建立的四域ICD编码能让肥胖型疾病的个性化诊断更加精确。
 
原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1910542, encodeId=6353191054224, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Fri Jun 05 00:01:00 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860491, encodeId=992c1860491cc, content=<a href='/topic/show?id=d064933e0b' target=_blank style='color:#2F92EE;'>#ICD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9337, encryptionId=d064933e0b, topicName=ICD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Thu Apr 02 03:01:00 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264062, encodeId=902012640621c, content=<a href='/topic/show?id=847353580bf' target=_blank style='color:#2F92EE;'>#慢性病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53580, encryptionId=847353580bf, topicName=慢性病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c49e75, createdName=qjddjq, createdTime=Thu Feb 27 12:01:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461775, encodeId=cc661461e7592, content=<a href='/topic/show?id=92c2132003b' target=_blank style='color:#2F92EE;'>#Obesity#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13200, encryptionId=92c2132003b, topicName=Obesity)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45616444603, createdName=lingaifan, createdTime=Thu Feb 27 12:01:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584764, encodeId=7dc81584e64fa, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Thu Feb 27 12:01:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588416, encodeId=b72515884161d, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Thu Feb 27 12:01:00 CST 2020, time=2020-02-27, status=1, ipAttribution=)]
    2020-06-05 zhanglin3079
  2. [GetPortalCommentsPageByObjectIdResponse(id=1910542, encodeId=6353191054224, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Fri Jun 05 00:01:00 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860491, encodeId=992c1860491cc, content=<a href='/topic/show?id=d064933e0b' target=_blank style='color:#2F92EE;'>#ICD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9337, encryptionId=d064933e0b, topicName=ICD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Thu Apr 02 03:01:00 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264062, encodeId=902012640621c, content=<a href='/topic/show?id=847353580bf' target=_blank style='color:#2F92EE;'>#慢性病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53580, encryptionId=847353580bf, topicName=慢性病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c49e75, createdName=qjddjq, createdTime=Thu Feb 27 12:01:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461775, encodeId=cc661461e7592, content=<a href='/topic/show?id=92c2132003b' target=_blank style='color:#2F92EE;'>#Obesity#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13200, encryptionId=92c2132003b, topicName=Obesity)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45616444603, createdName=lingaifan, createdTime=Thu Feb 27 12:01:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584764, encodeId=7dc81584e64fa, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Thu Feb 27 12:01:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588416, encodeId=b72515884161d, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Thu Feb 27 12:01:00 CST 2020, time=2020-02-27, status=1, ipAttribution=)]
    2020-04-02 yilong5287542
  3. [GetPortalCommentsPageByObjectIdResponse(id=1910542, encodeId=6353191054224, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Fri Jun 05 00:01:00 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860491, encodeId=992c1860491cc, content=<a href='/topic/show?id=d064933e0b' target=_blank style='color:#2F92EE;'>#ICD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9337, encryptionId=d064933e0b, topicName=ICD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Thu Apr 02 03:01:00 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264062, encodeId=902012640621c, content=<a href='/topic/show?id=847353580bf' target=_blank style='color:#2F92EE;'>#慢性病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53580, encryptionId=847353580bf, topicName=慢性病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c49e75, createdName=qjddjq, createdTime=Thu Feb 27 12:01:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461775, encodeId=cc661461e7592, content=<a href='/topic/show?id=92c2132003b' target=_blank style='color:#2F92EE;'>#Obesity#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13200, encryptionId=92c2132003b, topicName=Obesity)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45616444603, createdName=lingaifan, createdTime=Thu Feb 27 12:01:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584764, encodeId=7dc81584e64fa, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Thu Feb 27 12:01:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588416, encodeId=b72515884161d, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Thu Feb 27 12:01:00 CST 2020, time=2020-02-27, status=1, ipAttribution=)]
    2020-02-27 qjddjq
  4. [GetPortalCommentsPageByObjectIdResponse(id=1910542, encodeId=6353191054224, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Fri Jun 05 00:01:00 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860491, encodeId=992c1860491cc, content=<a href='/topic/show?id=d064933e0b' target=_blank style='color:#2F92EE;'>#ICD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9337, encryptionId=d064933e0b, topicName=ICD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Thu Apr 02 03:01:00 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264062, encodeId=902012640621c, content=<a href='/topic/show?id=847353580bf' target=_blank style='color:#2F92EE;'>#慢性病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53580, encryptionId=847353580bf, topicName=慢性病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c49e75, createdName=qjddjq, createdTime=Thu Feb 27 12:01:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461775, encodeId=cc661461e7592, content=<a href='/topic/show?id=92c2132003b' target=_blank style='color:#2F92EE;'>#Obesity#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13200, encryptionId=92c2132003b, topicName=Obesity)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45616444603, createdName=lingaifan, createdTime=Thu Feb 27 12:01:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584764, encodeId=7dc81584e64fa, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Thu Feb 27 12:01:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588416, encodeId=b72515884161d, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Thu Feb 27 12:01:00 CST 2020, time=2020-02-27, status=1, ipAttribution=)]
    2020-02-27 lingaifan
  5. [GetPortalCommentsPageByObjectIdResponse(id=1910542, encodeId=6353191054224, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Fri Jun 05 00:01:00 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860491, encodeId=992c1860491cc, content=<a href='/topic/show?id=d064933e0b' target=_blank style='color:#2F92EE;'>#ICD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9337, encryptionId=d064933e0b, topicName=ICD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Thu Apr 02 03:01:00 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264062, encodeId=902012640621c, content=<a href='/topic/show?id=847353580bf' target=_blank style='color:#2F92EE;'>#慢性病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53580, encryptionId=847353580bf, topicName=慢性病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c49e75, createdName=qjddjq, createdTime=Thu Feb 27 12:01:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461775, encodeId=cc661461e7592, content=<a href='/topic/show?id=92c2132003b' target=_blank style='color:#2F92EE;'>#Obesity#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13200, encryptionId=92c2132003b, topicName=Obesity)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45616444603, createdName=lingaifan, createdTime=Thu Feb 27 12:01:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584764, encodeId=7dc81584e64fa, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Thu Feb 27 12:01:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588416, encodeId=b72515884161d, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Thu Feb 27 12:01:00 CST 2020, time=2020-02-27, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1910542, encodeId=6353191054224, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Fri Jun 05 00:01:00 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860491, encodeId=992c1860491cc, content=<a href='/topic/show?id=d064933e0b' target=_blank style='color:#2F92EE;'>#ICD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9337, encryptionId=d064933e0b, topicName=ICD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Thu Apr 02 03:01:00 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264062, encodeId=902012640621c, content=<a href='/topic/show?id=847353580bf' target=_blank style='color:#2F92EE;'>#慢性病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53580, encryptionId=847353580bf, topicName=慢性病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c49e75, createdName=qjddjq, createdTime=Thu Feb 27 12:01:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461775, encodeId=cc661461e7592, content=<a href='/topic/show?id=92c2132003b' target=_blank style='color:#2F92EE;'>#Obesity#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13200, encryptionId=92c2132003b, topicName=Obesity)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45616444603, createdName=lingaifan, createdTime=Thu Feb 27 12:01:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584764, encodeId=7dc81584e64fa, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Thu Feb 27 12:01:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588416, encodeId=b72515884161d, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Thu Feb 27 12:01:00 CST 2020, time=2020-02-27, status=1, ipAttribution=)]
    2020-02-27 skhzy

相关资讯

减重手术已更名为代谢手术!阜外医院学者发文称,减肥是治疗冠心病、肥胖伴糖尿病的基础

肥胖患者发生糖尿病及冠心病的风险显着升高。而对于肥胖伴糖尿病的冠心病患者,其治疗更具挑战性。

Ann Neurol:肥胖与脑血管疾病

由此可见,腹部肥胖可能触发脑血管疾病病理过程,部分不依赖于血压,但与葡萄糖水平无关。这些病理过程的潜在靶标可能是卒中新的治疗机会。

Lancet Diabetes Endo:青少年肥胖与肿瘤风险

青少年肥胖导致肿瘤风险增加,并导致肿瘤死亡率增加

Circulation:33年随访研究:肥胖与女性心肌病风险的相关性

心肌病是年轻人心力衰竭的常见原因,发病率在过去几十年里有所上升。近期有研究表明,青春期体重与未来男性心肌病之间存在联系。而在女性中是否也是如此尚未明确。本研究拟探究年轻女性过重或肥胖是否与心肌病风险增高相关。本研究是一项国家级前瞻性队列研究,数据收集自1982年至2014年的瑞典出生登记,随访长达33年。纳入处于育龄期(18-45岁)女性(1,393,346人),在她们首次或二次妊娠时第一次产检时

Arthritis Rheumatol:内脏性肥胖与疼痛相关,但与结构性骨关节炎无关

内脏脂肪与肌肉骨骼和广泛性疼痛的风险升高相关。

Prostate Cancer P D:前列腺中肥胖相关的炎症能够诱导雄激素到雌激素的转换

有研究人员在他们的患者群体中发现肥胖与2型类固醇-5α还原酶(SRD5A2)启动子的甲基化和蛋白表达的减少具有很强的相关性。而该群体中前列腺增长的潜在机制仍旧不清楚。最近,他们探究了肥胖、炎症和类固醇激素是怎样影响良性前列腺增生(BPH)的。研究人员使用了前脂肪细胞、巨噬细胞、原代人前列腺基质细胞、高脂饮食诱导的肥胖小鼠的前列腺组织和35例来源于经历了经尿道前列腺切除术(TURP)患者的前列腺样本